Clinical trials: Digestive Infection
Non-alcoholic Fatty Liver Disease
Prospective Cohort Assessing the Role of the Genotoxin Colibactin From Escherichia Coli B2 in the Genesis of NASH
In a population of patients with Non Alcoholic Fatty Liver Disease (NAFLD), the investigators will compare the composition of the gut microbiota from patients with simple steatosis with that with steatohepatitis.
- Trial name
- Coli-NASH (NCT02390232)
- Testing
- liver biopsy, collection of stools, blood sample
- Where
- France
- Volunteers
- 176 people
- Sponsor
- University Hospital, Toulouse
HIV and Hepatitis B Coinfection
TAF for HIV-HBV With Renal Dysfunction
The investigators aim at describing changes in renal glomerular and tubular function with after the switch from TDF to TAF in HIV/HBV-coinfected patients with mild to moderate renal dysfunction and to assess the virological…
- Trial name
- NCT03115736
- Testing
- Tenofovir Alafenamide
- Where
- 8 sites in Switzerland
- Volunteers
- 24 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Rift Valley Fever
Study to Evaluate Safety, Tolerability and Pharmacokinetics of IDB-011
Phase 1 randomized, double-blind, placebo-controlled trial to evaluate safety, tolerability, pharmacokinetics (PK) and immunogenicity of IDB-011 following intramuscular (IM )administration of single ascending doses to healthy…
- Trial name
- NCT06925919
- Testing
- IDB-011 dose level 1, IDB-011 dose level 2, IDB-011 dose level 3
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- IDBiologics, Inc.
Cirrhosis, Portal Hypertension
A Study Evaluating the Utility of Ambrisentan in Lowering Portal Pressure in Patients With Liver Cirrhosis
Endothelin is a human hormone which has been associated with increased portal pressure in patients with liver cirrhosis (also called portal hypertension). Ambrisentan blocks the effects of endothelin.
- Conditions
- Cirrhosis, Portal Hypertension, Ascites
- Trial name
- NCT03827200
- Testing
- Ambrisentan
- Where
- 6 sites in Spain
- Volunteers
- 19 people
- Sponsor
- Noorik Biopharmaceuticals AG
Chronic Hepatitis B Infection
The Changes of CD4+T Cells Frequency and Function During Antiviral Therapy
Pegylated interferon α-2a(Peg-IFN-α) not only inhibit viral replication, but also play an important role in immune regulation, while Nucleoside analog(ue) drugs only inhibit viral replication.
- Trial name
- NCT03209011
- Testing
- Peginterferon Alfa-2a
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Yao Xie
Diarrhea, Helminthiasis
The Effect of an Urban Sanitation Intervention on Child Health
The purpose of this study is to determine the health impact of a basic sanitation intervention in Maputo, Mozambique.
- Trial name
- MapSan (NCT02362932)
- Testing
- Sanitation
- Where
- Mozambique
- Volunteers
- 1,866 people
- Sponsor
- London School of Hygiene and Tropical Medicine
HEPATITIS B CHRONIC
Phase 1 Study to Evaluate Safety and Antiviral Activity of PBGENE-HBV in Adult Patients With Chronic Hepatitis B
This is a Phase 1, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, and antiviral activity of PBGENE-HBV in adult participants with chronic hepatitis B.
- Trial name
- ELIMINATE-B (NCT06680232)
- Testing
- PBGENE-HBV
- Where
- 7 sites in United States, France and 4 more
- Volunteers
- 45 people
- Sponsor
- Precision BioSciences, Inc.
Hepatitis C Virus Infection, Response to Therapy of
Effects of Activity and Education Program on Patients With Chronic Hepatitis C Infection
This 4-year project will be guided by a biobehavioral model for the study of exercise interventions in two phases with the purposes to : 1.
- Trial name
- NCT01572233
- Testing
- Personalized Physical Activity and Psycho-Education (PPAPE) Program
- Where
- Taiwan
- Volunteers
- 300 people
- Sponsor
- National Taiwan University Hospital
HIV Infections, Hepatitis C
Effects of HIV and Hepatitis C Virus on the Brain
This study will determine the effects that HIV and hepatitis C virus have on thinking abilities and whether the viruses affect brain chemistry.
- Trial name
- NCT00494936
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Chronic Hepatitis B
Molecular Characteristics of Hepatitis B Virus Integration, Mutation, and Drug Resistance
Patients with a confirmed diagnosis of chronic hepatitis B (CHB) who have complete clinical data and retained blood or liver tissue samples will be enrolled.
- Trial name
- HBV IMDR (NCT06779864)
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Beijing Friendship Hospital
Healthy Volunteer
Efficacy of B7A BSIgG Against E. Coli Strain B7A Challenge
Enterotoxigenic Escherichia coli (ETEC) is a major cause of diarrhea worldwide. Vaccines and therapeutics are under development to prevent ETEC disease in children and travelers.
- Trial name
- NCT03040687
- Testing
- Anti CS6 BSIgG product (Lot PD1601105CS), Anti B7A BSIgG product (Lot PD1601132ET), Bovine Immunoglobin Negative Control (Lot PD161071NC)
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
NAFLD, NASH - Nonalcoholic Steatohepatitis
Vitamin E for NASH Treatment in HIV Infected Individuals
The purpose of this study is to see how taking Vitamin E daily affects fatty liver in persons living with HIV. Subjects will have both HIV and a fatty liver and the purpose of the study is to learn if underlying liver condition…
- Conditions
- NAFLD, NASH - Nonalcoholic Steatohepatitis, HIV Infections
- Trial name
- NCT03669133
- Testing
- Vitamin E
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Indiana University
Hepatitis B
Phase 1 Study of GSK3228836 Pharmacokinetics in Participants With Hepatic Impairment
This is a Phase 1, open-label, parallel-group study to evaluate the pharmacokinetics of GSK3228836 in participants with Child-Pugh B (CP-B) cirrhosis (moderate hepatic impairment), Child-Pugh A (CP-A) cirrhosis (mild hepatic…
- Trial name
- NCT04971928
- Testing
- GSK3228836
- Where
- 2 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hepatitis B
Efficacy of Peg-interferon α-2a in Hepatitis B Patients Treated by Entecavir Without HBeAg Loss
For HBeAg (+) hepatitis B patients who have been treated by entecavir for 48 weeks but without HBeAg loss, switching to peg-interferon may increase the response rate.
- Trial name
- NCT01599130
- Testing
- Entecavir, Peginterferon alfa-2a
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Sun Yat-sen University
Appendicitis Acute
First Appendectomy Using Revolve Surgical Robotic Arm
This study is testing a new surgical device called the Revolve Surgical System (RSS) during appendix removal surgery. The RSS is designed to help surgeons perform minimally invasive surgery with improved precision and stability…
- Trial name
- NCT07455487
- Testing
- Revolve Surgical System - RSS
- Volunteers
- 3 people
- Sponsor
- Unity Health Toronto
Liver Fibrosis Progression in Chronic Liver Disease
LIVER FIBROSIS PREVALENCE IN FRANCE
"Mortality related to complications of cirrhosis, (hemorrhage, hepatic insufficiency and primary liver cancer) is 15,000 per year in France.
- Trial name
- FIBROFRANCE (NCT01927133)
- Where
- France
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Chronic Hepatitis b
TAF Real World Study for Universal Effectiveness
This study is a multi-center, prospective, real-world study, males and non-pregnant, non-lactating female HBeAg positive or negative patients (above 18 years of age) who were mono-infected with HBV, either NA treatment-naïve or…
- Trial name
- TRUE (NCT03752658)
- Testing
- Tenofovir Alafenamide
- Where
- 7 sites in China
- Volunteers
- 500 people
- Sponsor
- Tongji Hospital
Chronic Hepatitis C Virus
Randomized Controlled Open Label Trial of Peg Alpha 2a Interferon and Adjusted-dose of Ribavirin vs. Standard Therapy in the Treatment of Naive Chronic Hepatitis C Patients Infected With Genotype 4
The study aims to study the outcome of pharmacokinetics-adjusted dose ribavirin (plus pegIFN) on the SVR in chronic HCV patients.
- Trial name
- NCT01686789
- Testing
- Pegylated interferon alpha-2a
- Where
- 3 sites in Saudi Arabia
- Volunteers
- 181 people
- Sponsor
- King Abdulaziz Medical City
Hepatitis C, Substance Use Disorders
Hepatitis C Treatment in PWIDs: MAT or Syringe Exchange Assisted-therapy vs Standard of Care
hepatitis C virus (HCV) has traditionally been treated in subspecialty health centers given the complexity of older pegylated interferon containing regimens, formerly the standard of care.
- Conditions
- Hepatitis C, Substance Use Disorders, Substance Abuse, Intravenous
- Trial name
- NCT03093415
- Testing
- elbasvir-grazoprevir (50 mg/100 mg)
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- Oregon Health and Science University
Cystic Fibrosis, Periodontitis
Cystic Fibrosis and Periodontal Diseases
The number of CF adults is increasing year after year (61.7% in 2021) confirming that patients are living longer. These data do not leave aside the desire to see CF patients "age well" considering of all the comorbidities linked…
- Conditions
- Cystic Fibrosis, Periodontitis, Gingivitis
- Trial name
- MucoParo (NCT06133335)
- Testing
- Periodontal examination
- Where
- France
- Volunteers
- 50 people
- Sponsor
- CHU de Reims